Pharmacognosy · TRPV1 Agonist

Cayenne Pepper

Capsicum annuum L. — The botanical source of capsaicin: a potent TRPV1 agonist underpinning an FDA-approved neuropathic pain treatment, whose pungent alkaloid delivers analgesic, thermogenic, and anti-inflammatory effects through receptor desensitisation.

2 Primary Refs
10+ Properties
Fruit Parts Used
✦ Researched
Last Updated
Primary Source Wikiphyto · NCBI PubMed
Family Solanaceae
Evidence Grade A (Topical Analgesia) · FDA & EMA Approved

Biological Overview

Capsicum annuum is a member of the nightshade family (Solanaceae) cultivated worldwide for its pungent fruits. The plant's remarkable pharmacological potency derives from capsaicin — an alkaloid vanillyl amide that is the most studied natural TRPV1 agonist in medicine. Capsaicin's analgesic mechanism is unique in pharmacology: it works by overstimulating pain receptors until they become temporarily unable to signal pain, producing prolonged relief from a single application.

Key ActiveCapsaicin (trans-8-methyl-N-vanillyl-6-nonenamide)
Primary TargetTRPV1 receptor · Substance P depletion · C-fibre defunctionalisation
FDA StatusApproved (Qutenza 8% patch) — PHN & Diabetic Neuropathy
Scoville Range30,000 – 50,000 SHU (cayenne variety)
Botanical Classification

Taxonomy & Identification

Latin Name
Capsicum annuum L.
Family
Solanaceae
Common Names
Cayenne Pepper, Red Pepper, Chilli Pepper, Bird Pepper
French Name
Piment de Cayenne, Piment rouge
Parts Used
Dried ripe fruit (separated from calyx)
Key Active
Capsaicin (~70% of capsaicinoids)
Origin
Tropical Americas; cultivated globally
Ethnobotany

History & Tradition

Capsicum species have been cultivated in Central and South America for over 6,000 years, making them among the oldest cultivated plants in the Western hemisphere. Archaeological evidence from Mexico and Peru confirms their widespread use well before European contact. The Aztecs and Maya used cayenne both as a condiment and as a topical treatment for pain and inflammation — an application that would eventually be validated by modern receptor pharmacology.

Following the Columbian Exchange, chilli peppers spread globally with remarkable speed. By the 16th century they had become a dietary staple across Africa, Asia, and Europe. Capsaicin was first isolated in impure form by Christian Friedrich Bucholz in 1816, and in its pure crystalline form by John Clough Thresh in 1846. Its chemical structure was determined by Ernest Spaeth and Stephen Darling in 1930.

The modern pharmacological era began in 1997 when David Julius and colleagues at UCSF cloned the TRPV1 receptor — the molecular target of capsaicin — a discovery that earned Julius the 2021 Nobel Prize in Physiology or Medicine. This breakthrough explained two millennia of empirical use and opened the path to FDA-approved capsaicin therapeutics.

🏅

2021 Nobel Prize — Physiology or Medicine

David Julius (UCSF) was awarded the Nobel Prize jointly with Ardem Patapoutian for the discovery of TRPV1 — using capsaicin as the molecular probe that unlocked the mechanism of pain and heat perception. Every capsaicin-based analgesic in clinical use today is a direct descendant of this discovery.

Key Historical Milestones

~4000 BCE Cultivation in Central America — earliest evidence
1492 Columbus brings peppers to Europe — Columbian Exchange begins
1816 Capsaicin first isolated in impure form by Bucholz
1912 Wilbur Scoville develops the Scoville Heat Unit scale
1997 TRPV1 receptor cloned by Julius et al. — mechanism explained
2009 FDA approves Qutenza 8% capsaicin patch for PHN
2021 Nobel Prize — David Julius · Second FDA approval for diabetic peripheral neuropathy
Phytochemistry

Composition

The fruit contains a rich ensemble of capsaicinoids, carotenoids, flavonoids, and vitamins — though it is the capsaicinoid fraction that dominates both culinary and pharmacological significance.

Capsaicinoids (Pungent Fraction)

Capsaicin~70% of total capsaicinoids; primary pungent alkaloid; selective TRPV1 agonist; trans-8-methyl-N-vanillyl-6-nonenamide (C₁₈H₂₇NO₃)
Principal
Dihydrocapsaicin~20% of total capsaicinoids; similar potency to capsaicin; TRPV1 agonist
Major
Nordihydrocapsaicin~7%; slightly less pungent than capsaicin; TRPV1 agonist
Minor
Homodihydrocapsaicin & Homocapsaicin~1–3% each; minor capsaicinoids with comparable receptor activity
Trace
Capsiate (Capsinoids)Non-pungent analogues; activate TRPV1 in the gut without oral burning; thermogenic activity without pungency
Variant

Other Bioactive Constituents

CarotenoidsCapsanthin, capsorubin (red pigments), β-carotene, zeaxanthin — potent antioxidants; responsible for the characteristic red colour
Antioxidant
VitaminsExceptionally rich in Vitamin C (up to 200 mg/100 g fresh weight — 3× that of oranges); Vitamin A (from carotenoids); Vitamin E, B6
Nutritional
FlavonoidsQuercetin, luteolin, apigenin — anti-inflammatory and antioxidant activity
Present
Fixed Oil~12–15% in seeds; linoleic acid (principal fatty acid), oleic acid
Seeds
Steroidal SaponinsCapsicidins — documented antimicrobial activity against Candida species
Present
Pungency Science

The Scoville Scale

Developed by pharmacist Wilbur Scoville in 1912, the Scoville Heat Unit (SHU) scale quantifies capsaicinoid concentration in pepper fruits. Modern analysis uses high-performance liquid chromatography (HPLC) rather than human taste panels, providing precise and reproducible measurements.

Pepper Variety Scoville Heat Units Heat Level
Bell Pepper 0 SHU
Pepperoncini 100 – 500 SHU
Jalapeño 2,500 – 8,000 SHU
Serrano 10,000 – 23,000 SHU
Cayenne Pepper ← You are here 30,000 – 50,000 SHU
Habanero 100,000 – 350,000 SHU
Ghost Pepper (Bhut jolokia) 800,000 – 1,000,000 SHU
Carolina Reaper 1,500,000 – 2,200,000 SHU
Pure Capsaicin ~16,000,000 SHU

How Scoville Works

The original Scoville Organoleptic Test (1912) diluted pepper extract in sugar water until a panel of five tasters could no longer detect heat. The dilution factor at this threshold defined the SHU.

Modern HPLC analysis directly measures capsaicinoid concentration and converts to SHU mathematically (1 part capsaicin per million = 16.1 SHU), eliminating human subjectivity and producing legally defensible measurements for food labelling.

Why Heat = Analgesia

The burning sensation of capsaicin and its analgesic effect share the same molecular mechanism — TRPV1 activation. The initial burning depletes substance P from nerve terminals; repeated exposure leaves those terminals temporarily unable to signal pain. Higher SHU peppers deplete substance P faster, but require more careful handling in clinical contexts.

Receptor Pharmacology

The TRPV1 Receptor

The entire pharmacology of capsaicin converges on a single molecular target: the Transient Receptor Potential Vanilloid 1 (TRPV1) channel — a discovery that earned the 2021 Nobel Prize in Physiology or Medicine.

🎯

What is TRPV1?

TRPV1 is a calcium-permeable, non-selective cation channel expressed on the terminals of unmyelinated C-fibres and thinly myelinated Aδ nociceptors throughout the body. It functions as a polymodal sensor: activated by noxious heat (above 43 °C), acidic pH (below 6.0), and endogenous lipids — as well as by exogenous agonists such as capsaicin. It was cloned in 1997 by David Julius's laboratory at UCSF using capsaicin as a molecular probe, a landmark achievement in pain neuroscience.

⚡

Phase 1 — Activation & Burning

Capsaicin binds to the intracellular face of TRPV1, opening the channel and allowing a large influx of calcium ions (Ca²⁺) and sodium ions into the nociceptor terminal. This depolarises the neurone, triggering action potentials perceived as burning pain. Simultaneously, substance P and calcitonin gene-related peptide (CGRP) are released from the terminal — neuropeptides that mediate neurogenic inflammation and pain transmission in the dorsal horn of the spinal cord.

🔇

Phase 2 — Desensitisation & Analgesia

Sustained Ca²⁺ influx triggers multiple desensitisation mechanisms: calcineurin-mediated dephosphorylation of TRPV1, depletion of PIP₂ (a membrane lipid required for TRPV1 function), and calcium-dependent inactivation. The terminal becomes transiently unresponsive to further stimuli — a state termed "defunctionalisation." This is the molecular basis of capsaicin analgesia. Importantly, the process is reversible: nerve function fully recovers over weeks to months.

🧬

Substance P Depletion

Substance P is the primary neuropeptide responsible for transmitting pain signals from peripheral nociceptors to the spinal cord. Capsaicin causes its rapid release followed by depletion — the terminal cannot replenish substance P fast enough to keep pace with ongoing stimulation. A 2008 review in Current Anaesthesia & Critical Care (Hayman & Kam) confirmed this as the principal mechanism underlying topical capsaicin analgesia for chronic pain conditions including postherpetic neuralgia and osteoarthritis.

Activation Stimuli Capsaicin · Heat (>43°C) · Acidic pH (<6.0) · Endocannabinoids · Inflammatory lipids
Expression Sites C-fibres · Aδ-fibres · Dorsal root ganglia · Bladder · GI tract · Airways

Plant Properties — Pharmacodynamics

Whole-fruit biological activities across multiple organ systems

10+ Properties FDA Approved (Topical) Nobel Prize Target

Analgesic — TRPV1 Mediated

The primary clinical property. Capsaicin produces prolonged analgesia through TRPV1 receptor desensitisation and substance P depletion from nociceptor terminals. The 8% capsaicin patch (Qutenza) is FDA-approved for postherpetic neuralgia and diabetic peripheral neuropathy. A Cochrane systematic review (Derry et al., 2017) confirmed that a single 8% patch application provided significant pain relief lasting up to 12 weeks with a number needed to treat (NNT) of 6–9. [1]

Rubefacient & Counter-Irritant

At lower concentrations (0.025–0.075% cream), capsaicin acts as a rubefacient — stimulating local blood flow, warmth, and a counter-irritant effect that reduces pain perception through competing sensory signals (gate control theory). Low-concentration OTC creams (Zostrix, Capzasin-P) are widely used for osteoarthritis and musculoskeletal pain. A systematic review in BMJ (Mason et al., 2004) found statistically significant benefit over placebo for chronic musculoskeletal pain. [2]

Anti-Inflammatory

Capsaicin inhibits NF-κB signalling — the master transcription factor governing pro-inflammatory cytokine production — and reduces COX-2 expression. Quercetin and luteolin from the fruit flavonoid fraction contribute additional anti-inflammatory activity through lipoxygenase inhibition. In vitro and animal studies confirm significant reduction in TNF-α, IL-1β, and IL-6. Clinical anti-inflammatory applications include rhinitis and cluster headache prophylaxis.

Thermogenic & Metabolic

Capsaicin activates brown adipose tissue (BAT) thermogenesis via sympathetic nervous system stimulation through TRPV1 in the GI tract. A 2020 meta-analysis of 13 placebo-controlled RCTs (Akbari et al., Nutrients) confirmed that capsaicinoids/capsinoids significantly increase resting metabolic rate by ~34 kcal/day and enhance fat oxidation. A 2012 meta-analysis in Chemical Senses (Ludy et al.) confirmed modest but consistent appetite suppression. Effects are real but of limited magnitude for weight management.

Digestive Stimulant

Cayenne stimulates gastric acid secretion and enhances gastric motility through TRPV1 receptors expressed throughout the gastrointestinal tract. Paradoxically, despite the burning sensation, evidence suggests that capsaicin may protect the gastric mucosa at low dietary doses by stimulating mucus production and increasing mucosal blood flow — a gastroprotective effect documented in animal models. Traditional medicine systems from Ayurveda to Traditional Chinese Medicine have long used cayenne as a digestive tonic.

Antioxidant

The fruit is exceptionally rich in antioxidant compounds: carotenoids (capsanthin, capsorubin), vitamin C (among the highest concentrations of any plant food), vitamin E, and flavonoids. These act through multiple mechanisms including free radical scavenging, upregulation of Nrf2/HO-1 antioxidant response pathways, and inhibition of lipid peroxidation. The carotenoid profile is responsible for the characteristic red colour and has been associated with anti-cancer properties in observational studies.

Anti-Rhinitis (Intranasal)

Intranasal capsaicin desensitises nasal TRPV1 receptors on sensory fibres, reducing neurogenic inflammation and nasal hyperreactivity. A 2024 systematic review and meta-analysis (Clinical Reviews in Allergy & Immunology, Wang et al.) of 9 placebo-controlled studies found significant improvements in total nasal symptom scores and VAS scores in non-allergic rhinitis. Multiple double-blind RCTs (Van Rijswijk et al., 2003; Bernstein et al., 2011) support its use as a non-pharmacological treatment for vasomotor rhinitis.

Cardiovascular & Lipid-Lowering

A 2022 systematic review and meta-analysis (Frontiers in Nutrition, Jiang et al.) of RCTs in patients with metabolic syndrome found that capsaicin significantly reduced LDL-cholesterol (SMD −0.39) and showed a trend toward reduced body weight. TRPV1 activation in the cardiovascular system modulates vascular tone through CGRP release — a potent vasodilator. Dietary capsaicin has been associated with reduced cardiovascular mortality in large epidemiological studies from China and Italy.

Antimicrobial (Capsicidins)

Steroidal saponins in cayenne — collectively termed capsicidins — have demonstrated antimicrobial activity against Candida species and several bacterial strains in vitro. This property underpins traditional uses of pepper as a food preservative in tropical climates where refrigeration was historically unavailable and microbial contamination of food posed significant health risks. [1]

Anti-Proliferant (Preliminary)

In vitro studies and preclinical animal models demonstrate that capsaicin induces apoptosis in prostate, breast, bladder, and colorectal cancer cell lines through multiple mechanisms: NF-κB inhibition, activation of the apoptotic cascade via mitochondrial pathways, cell cycle arrest, and inhibition of angiogenesis. A 2022 two-decade systematic review (Frontiers in Oncology) catalogued 3,753 publications confirming these chemopreventive effects. Clinical translation remains in early stages — see Cancer Research section.

Clinical Applications

Clinical Indications

Indications organised by evidence strength — from FDA-approved applications through well-supported clinical uses to emerging research areas.

🩹
Topical Analgesia
FDA & EMA Approved · Highest Evidence
  • Postherpetic neuralgia (PHN): FDA-approved (Qutenza 8% patch, 2009); Cochrane review NNT 6–9; single application lasting up to 12 weeks
  • Diabetic peripheral neuropathy (DPN): second FDA approval (2021) for feet; 30-minute application; significant pain score reductions in RCTs with 369 participants
  • Peripheral neuropathic pain broadly: EMA-approved label for Qutenza covers all peripheral neuropathic pain in adults
  • Osteoarthritis pain: 0.025–0.075% cream four times daily; meta-analysis of 5 RCTs shows moderate efficacy (SMD 0.44) over 4 weeks; effective across knee, hand, and mixed joints (Zhang et al., Osteoarthritis Cartilage, 2014)
  • Chemotherapy-induced peripheral neuropathy (CIPN): 8% patch shows significant pain relief in 5 studies (systematic review, 2020)
👃
ENT & Headache
Clinical Evidence
  • Non-allergic (vasomotor) rhinitis: intranasal capsaicin spray; 2024 meta-analysis confirms significant TNSS improvement; multiple double-blind RCTs support use
  • Cluster headache: intranasal capsaicin has been explored in small trials; reduces frequency and severity through TRPV1 desensitisation in trigeminal fibres; evidence remains limited
  • Burning mouth syndrome: topical application and systemic capsaicin have been studied; mixed results in small trials
  • Dysphagia in elderly: preliminary findings suggest 0.025% capsaicin ointment applied to external auditory canal improves swallowing function (MSK Cancer Center review)
🔥
Metabolic & Digestive
Moderate Evidence
  • Thermogenesis / weight management adjunct: increases RMR ~34 kcal/day; enhances fat oxidation; modest appetite suppression — real but limited effect size
  • Dyslipidaemia in metabolic syndrome: LDL reduction confirmed in RCT meta-analysis (Jiang et al., 2022)
  • Digestive tonic: stimulates gastric secretion and motility; traditional use for dyspepsia and sluggish digestion
  • Cannabis hyperemesis syndrome: topical capsaicin cream to abdomen — multiple case reports and small series show relief; mechanism via cutaneous TRPV1 activation
🔬
Emerging & Investigational
Preclinical / Early Clinical
  • Prostate cancer adjuvant: chronic oral administration shown safe and effective in reducing metastatic burden in TRAMP mouse model; NF-κB inhibition and androgen receptor suppression mechanisms identified
  • Cardiovascular protection: large epidemiological data from China (500,000 participants, BMJ, 2015) and Italy associate regular chilli consumption with reduced all-cause and cardiovascular mortality
  • Bladder dysfunction: intravesical capsaicin explored for neurogenic bladder; TRPV1 expression in the bladder urothelium provides mechanistic rationale
Regulatory Status

FDA-Approved Applications

Capsaicin holds the distinction of being both a common food ingredient and the active ingredient in an FDA-approved prescription pharmaceutical — a rare dual status in plant medicine.

FDA Approved — 2009

Qutenza® — Postherpetic Neuralgia

The first FDA approval for Qutenza (capsaicin 8% patch, 179 mg, 640 mcg/cm²) was for the management of neuropathic pain associated with postherpetic neuralgia — the chronic nerve pain that persists after shingles infection, often lasting years and severely impacting quality of life.

Application Protocol

  • ▸ Applied by healthcare provider only
  • ▸ Single 60-minute application to affected area
  • ▸ Topical anaesthetic pre-treatment to manage burning
  • ▸ Pain relief lasts up to 12 weeks
  • ▸ Can be repeated every 3 months
FDA Approved — 2021

Qutenza® — Diabetic Peripheral Neuropathy

The second FDA approval extended Qutenza's indication to neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet — marking it as the first and only topical TRPV1 agonist approved for this indication and a non-opioid, non-systemic alternative for a condition affecting millions of people with diabetes.

DPN Application Protocol

  • ▸ Applied by healthcare provider only
  • ▸ Up to 4 patches for 30 minutes on the feet
  • ▸ No topical anaesthetic required (shorter duration)
  • ▸ Non-systemic — no drug interactions
  • ▸ No contraindications listed
EMA — European Medicines Agency

The European Medicines Agency has approved Qutenza for the broader label of peripheral neuropathic pain in adults, encompassing postherpetic neuralgia, HIV neuropathy, painful diabetic neuropathy, and other peripheral neuropathic conditions. This wider label reflects additional clinical data from EU trials and is more permissive than the US FDA label.

OTC Status — Low-Concentration Creams

Capsaicin creams at 0.025% and 0.075% concentration are available over the counter in the US and EU under brand names including Zostrix and Capzasin-P. These are indicated for temporary relief of minor pain associated with arthritis, back and muscle aches, and other musculoskeletal conditions. The Cochrane review on low-concentration capsaicin found insufficient evidence to recommend for neuropathic pain, but moderate evidence supports use in osteoarthritis.

Metabolic Pharmacology

Metabolic & Thermogenic Effects

Capsaicin's thermogenic properties operate through TRPV1 receptors in the gastrointestinal tract and adipose tissue, activating the sympathetic nervous system to increase energy expenditure and fat oxidation.

🔥

Brown Adipose Tissue Activation

Capsaicin activates TRPV1 receptors in the gastrointestinal tract, triggering sympathetic nervous system outflow that stimulates brown adipose tissue (BAT) thermogenesis. BAT burns calories to generate heat via uncoupling protein 1 (UCP1), a fundamentally different process from white adipose tissue energy storage. TRPV1 activation also promotes the "browning" of white adipocytes — increasing metabolic activity of previously inert fat stores — via AMPK and PPARα pathway activation.

📊

Meta-Analysis Evidence

A 2020 meta-analysis of 13 placebo-controlled trials (Akbari et al., Nutrients) found capsaicinoids significantly increased resting metabolic rate (WMD: +34 kcal/day), increased fat oxidation, and reduced the respiratory quotient — confirming a shift toward fat as a fuel substrate. A 2012 critical review and meta-analysis (Ludy et al., Chemical Senses) confirmed appetite suppression effects, particularly reduction in orexigenic sensations. Both reviews noted the magnitude of effect is modest and unlikely to produce meaningful weight loss without concurrent dietary modification.

💊

Capsinoids — Non-Pungent Alternative

Capsiate and dihydrocapsiate are structural analogues of capsaicin found in non-pungent "sweet" Capsicum varieties (CH-19 Sweet). They activate TRPV1 in the gut without triggering oral burning, making them a tolerable alternative for thermogenic supplementation. Available as supplements in the US ("CH-19 Sweet Extract"), they produce comparable metabolic effects to capsaicin without the gastrointestinal discomfort that limits higher-dose capsaicin use.

❤️

Cardiovascular & Epidemiological Data

A 2015 prospective study published in BMJ (Lv et al.) followed 487,375 participants in China over 7 years and found that regular consumption of spicy food — primarily chilli peppers — was associated with a 14% reduced risk of total mortality. A 2019 Italian study (Bonaccio et al., JACC) of 22,811 participants similarly found regular chilli pepper consumption associated with significantly reduced cardiovascular and cerebrovascular mortality. Mechanisms are considered multifactorial: anti-inflammatory, lipid-lowering, and vasodilatory effects all likely contribute.

Oncology Research

Cancer Research — What the Evidence Shows

Capsaicin demonstrates compelling preclinical anti-cancer activity. Clinical translation is early-stage. Presenting the evidence accurately — without overclaiming — is essential for any authority health resource.

Evidence Caveat

The majority of evidence for capsaicin's anti-cancer effects comes from in vitro cell line studies and animal models. While the mechanistic data is compelling and consistent across multiple cancer types and research groups, robust randomised controlled trials in human cancer patients are lacking. A two-decade systematic review (Olatunji et al., Frontiers in Oncology, 2022) of 3,753 publications explicitly noted that "clinical studies were limited." The data below should be interpreted as mechanistic and preliminary — not as clinical recommendations.

Prostate Cancer

The most extensively studied cancer model. Capsaicin inhibits growth of androgen-independent, p53-mutant prostate cancer cells (Mori et al., Cancer Research, 2006). It negatively regulates androgen receptor at mRNA and protein levels. Chronic oral administration in the TRAMP transgenic mouse model was safe and effectively reduced metastatic burden. NF-κB inhibition and apoptotic cascade activation are primary mechanisms. Clinical trials are being planned.

Breast & Bladder Cancer

In vitro studies demonstrate capsaicin-induced apoptosis in breast cancer cell lines through ROS-JNK-CHOP pathway activation, and in bladder cancer through cell cycle arrest. Memorial Sloan Kettering Cancer Center's integrative medicine resource lists antiproliferative effects against breast and bladder cell lines as documented but notes that clinical evidence remains insufficient to recommend capsaicin as a cancer treatment.

Controversy: Carcinogen or Chemopreventive?

A paradox exists in the literature. Some older studies suggested capsaicin might act as a co-carcinogen in gastric tissue at very high doses. Bode & Dong's 2011 review in Cancer Research titled "The Two Faces of Capsaicin" addressed this directly, concluding that at dietary doses capsaicin is chemopreventive, while extreme doses in specific contexts may have different effects. At typical human dietary intake levels, the epidemiological evidence favours a protective rather than harmful association.

Clinical Safety

Safety & Precautions

Capsaicin has a well-established safety profile at both dietary doses and OTC cream concentrations. The 8% prescription patch requires clinical supervision due to intense application-site reactions.

⚠️

Adverse Effects by Route

  • Topical (OTC cream): burning, stinging, redness, and itching at application site — particularly on first application; resolves with continued use as desensitisation develops. Avoid eyes, mucous membranes, and broken skin
  • Topical (8% Qutenza patch): intense application-site pain, erythema, and transient blood pressure increase during application — managed with topical anaesthetic pre-treatment and clinical supervision. Administered by healthcare providers only
  • Oral / dietary: GI irritation, heartburn, and diarrhoea at high doses; well tolerated at normal dietary levels. Chronic high intake may worsen pre-existing GI conditions
  • Intranasal: intense nasal burning and lacrimation immediately after application; resolves within minutes and decreases with repeated use
  • Inhalation: aerosolised capsaicin (e.g. chilli cooking vapour, pepper spray) causes severe respiratory irritation and bronchoconstriction — avoid in asthma patients
🚫

Contraindications & Interactions

  • Broken or inflamed skin: absolutely contraindicated for topical application to open wounds, active skin infections, or inflamed dermatosis
  • Hypersensitivity: known allergy to Capsicum species or any component of preparations; cross-reactivity with latex has been reported
  • ACE inhibitors: capsaicin may potentiate ACE inhibitor-induced cough through TRPV1 sensitisation in airway mucosa — use with caution
  • Anticoagulants: high-dose oral supplementation may theoretically enhance anticoagulant effects through platelet inhibition; monitor INR in patients on warfarin
  • Asthma / COPD: inhalation of capsaicin vapour is a significant bronchospasm trigger; avoid cooking with high-heat chilli preparations in confined spaces
  • Pregnancy and lactation: dietary use is considered safe; medicinal doses and supplements should be avoided; capsaicin is excreted in breast milk and may cause GI distress in nursing infants
  • Children: OTC topical preparations not recommended for children under 2 years without medical supervision
Clinical Disclaimer: This monograph is for educational and professional reference only. It does not constitute medical advice, diagnosis, or treatment guidance. Qutenza (8% capsaicin patch) is a prescription medicine that must be administered by a healthcare provider. For chronic pain conditions, consult a qualified clinician before initiating any capsaicin-based treatment. The Health Reference reviews content against current primary literature.
Common Questions

Frequently Asked Questions

How does capsaicin relieve pain if it initially causes burning?
This is the defining paradox of capsaicin pharmacology. The burning is caused by TRPV1 receptor activation on nociceptor nerve terminals, triggering calcium influx and action potentials. However, sustained activation depletes the terminal of substance P — the neuropeptide responsible for transmitting pain signals to the spinal cord. The terminal then enters a state of "defunctionalisation": it cannot signal pain because it has exhausted its neurotransmitter supply and its ion channels have desensitised. This produces prolonged analgesia lasting weeks to months from a single high-dose treatment, or from repeated lower-dose applications. The burning is the price of the cure — and it diminishes with each application as desensitisation sets in.
What is Qutenza and does it actually work?
Qutenza is an 8% capsaicin patch (179 mg total capsaicin) approved by the FDA in 2009 for postherpetic neuralgia and in 2021 for diabetic peripheral neuropathy. It is applied by a healthcare provider for 30–60 minutes and can provide significant pain relief for up to 12 weeks from a single treatment. A Cochrane systematic review (Derry et al., 2017) found the 8% patch provided meaningful pain relief (≥30% reduction) in approximately 35–40% of patients with postherpetic neuralgia compared with ~20% on placebo, with a number needed to treat (NNT) of 6–9. It is a non-opioid, non-systemic option with no drug interactions — a significant advantage for patients already on complex medication regimens.
What is the Scoville scale and how hot is cayenne?
The Scoville Heat Unit (SHU) scale measures the concentration of capsaicinoids in a pepper. Developed by pharmacist Wilbur Scoville in 1912 using human taste panels, modern measurement uses HPLC chromatography. Cayenne pepper typically measures 30,000–50,000 SHU — significantly hotter than jalapeños (2,500–8,000 SHU) but much milder than habaneros (100,000–350,000 SHU) or the Carolina Reaper (up to 2.2 million SHU). Pure capsaicin measures approximately 16,000,000 SHU. The SHU is directly proportional to analgesic potential — higher capsaicinoid concentrations produce more intense TRPV1 activation and more rapid substance P depletion.
Can cayenne pepper help with weight loss?
The thermogenic effect is real and scientifically validated. A 2020 meta-analysis of 13 RCTs found capsaicinoids increase resting metabolic rate by approximately 34 kcal/day and shift substrate oxidation toward fat. However, 34 kcal/day represents less than 2% of the average adult's total daily energy expenditure — a meaningful signal at the population level, but unlikely to produce noticeable weight loss on its own. Capsaicin and its non-pungent analogue capsiate also suppress appetite modestly. The honest evidence-based answer: capsaicin can support a weight management programme but is not a meaningful standalone intervention for weight loss.
Does cayenne pepper damage the stomach lining?
Counterintuitively, the evidence suggests that capsaicin at dietary doses is gastroprotective rather than harmful in most people. Capsaicin stimulates gastric mucus production, increases mucosal blood flow, and activates protective prostaglandin synthesis — effects that strengthen rather than damage the mucosal barrier. Epidemiological data from spice-consuming populations in Asia and Latin America do not show increased rates of peptic ulcer disease. However, at supra-dietary supplemental doses, capsaicin can cause GI irritation, reflux, and diarrhoea — particularly in people with existing GI conditions such as irritable bowel syndrome or inflammatory bowel disease. People with active peptic ulcers, GERD, or IBD should exercise caution with high-dose supplementation.
Is there evidence capsaicin fights cancer?
There is compelling preclinical evidence — primarily from cell line studies and animal models — that capsaicin induces apoptosis in multiple cancer types including prostate, breast, bladder, and colorectal cancer cells. The mechanisms are well-characterised: NF-κB inhibition, mitochondrial apoptotic pathway activation, cell cycle arrest, and anti-angiogenic effects. However, translating these findings to clinical practice remains challenging. As of 2024, there are no completed large-scale clinical trials establishing capsaicin as a cancer treatment in humans. The evidence warrants continued research and is scientifically interesting — but is not sufficient to recommend capsaicin as a cancer therapy outside of a clinical trial setting.
Primary Literature

Bibliography

↑ 1. Hayman M, Kam PCA. Capsaicin: a review of its pharmacology and clinical applications. Curr Anaesth Crit Care. 2008;19(5):338–343. PubMed PMID:18380920 →
↑ 2. Reyes-Escogido ML, Gonzalez-Mondragon EG, Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. Molecules. 2011;16(2):1253–1270. PubMed PMID:17365137 →

Additional Reference Literature

Bruneton J. Pharmacognosie, Phytochimie, Plantes médicinales. 4th ed. Ed. Tec et Doc / Lavoisier. Paris. 2009.
Chiej R. Encyclopédie des plantes médicinales. Ed. Elsevier/Time-Life. 1984.
Wichtl M, Anton R. Plantes thérapeutiques. Edition française. Tec-Doc EMI Editeurs. Paris. 1999.
Duke JA. Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants. CRC Press. 1992.